Why the study?
Do antiplatelet agents reduce the risk of recurrent stroke and vascular events in patients with a history of stroke or TIA?
Population
Patients with a history of stroke, transient ischemic attack, or other vascular disease requiring secondary…
Comparison
Antiplatelet agents including aspirin… vs Placebo or alternative antiplatelet agents.
Design
Review
Authors
Loading...
Supports aspirin as first-line post-TIA prevention; leaves open optimal sequencing with newer agents in contemporary cohorts.
Do antiplatelet agents reduce the risk of recurrent stroke and vascular events in patients with a history of stroke or TIA?
Aspirin is the first-line therapy for secondary stroke prevention, with clopidogrel serving as a safe and effective alternative for patients intolerant to aspirin.
Paciaroni et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: